Search Results 71-80 of 17115 for ulcerative colitis

  1. A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) - Mayo Clinic

    The purpose of this study is to determine the long-term safety of vedolizumab intravenous (IV) treatment in pediatric participants with Ulcerative Colitis (UC) ...

  2. A Study to Evaluate both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or ...

  3. Mayo Clinic Q&A podcast Dr. Faubion IBD

    If you take a look at all forms of inflammatory bowel disease, both Crohn's disease and ulcerative colitis, the incidence has actually been increasing. Narrator ...

  4. Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

  5. Mesalamine (Oral Route) Proper Use - Mayo Clinic

    Dosing · For the treatment of ulcerative colitis: For long-acting oral dosage form (delayed-release capsules):. Adults—800 milligrams (mg) 3 times a day. · For ...

  6. Long-Term Safety of PF-00547659 in Ulcerative Colitis - Mayo Clinic

    Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 72 weeks of open-label treatment to ...

  7. AMG 181 Phase 2 Study in Subjects with Moderate to Severe Ulcerative Colitis - Mayo Clinic

    AMG 181 Phase 2 Study in Subjects with Moderate to Severe Ulcerative Colitis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility ...

  8. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

  9. Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies - Mayo Clinic

    ... ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in ...

  10. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...